Contribute Try STAT+ Today

AbbVie said Tuesday it will acquire Allergan for $63 billion — the latest megamerger between two pharma giants seeking new ways to grow.

The deal, combining two firms built by past acquisitions, represents a solution to existential problems facing both companies. Allergan has faced questions over its potential for growth, its moves to extend its patents, and its ability to develop experimental drugs. AbbVie markets the best-selling drug in the world, Humira, which has annual sales of $20 billion, but investors worry that it will not be able to maintain those revenues after patents on the drug expire. The big prize for AbbVie is Allergan’s franchise of aesthetics drugs, including Botox, which has annual sales of $3.6 billion.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.